Decoy Therapeutics Inc. (DCOY)
NCM – Real vaqt narxi. Valyuta: USD
5.15
-0.29 (-5.33%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NCM – Real vaqt narxi. Valyuta: USD
5.15
-0.29 (-5.33%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Decoy Therapeutics Inc. preklinik bosqichdagi biotexnologiya kompaniyasi sifatida faoliyat yuritadi. U peptide coiled-coils kimyosi va fizikasidan foydalanadigan Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platformasi orqali peptid kon'yugatli terapevtik vositalarni ishlab chiqishga qaratilgan bo'lib, hisoblash va ML vositalari yordamida α-spiral peptidlarni loyihalashtiradi. Kompaniyaning IMP3ACT platformasi turli xil tibbiy ehtiyojlarga mo'ljallangan peptid kon'yugatlarini ishlab chiqish, takomillashtirish va ishlab chiqarish uchun sintez usullari bilan bir qatorda mashinani o'rganish va sun'iy intellekt vositalaridan foydalanadi. U yuqumli kasalliklar va onkologiyaga qaratilgan peptid kon'yugatli terapevtik vositalar portfelini yaratishga e'tibor qaratadi. Kompaniya ilgari Salarius Pharmaceuticals, Inc. nomi bilan tanilgan va 2026 yil yanvar oyida Decoy Therapeutics Inc. nomini o'zgartirgan. Decoy Therapeutics Inc. Xyuston, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Barbara Hibner Ph.D. | Chief Scientific Officer |
| Dr. Nadeem Q. Mirza M.D., M.P.H. | Senior Vice President of Clinical Development |
| Mr. Frederick E. Pierce II | CEO & Director |
| Mr. Mark J. Rosenblum CPA | Executive VP of Finance & CFO |
| Mr. Peter K. Marschel M.B.A., M.S. | Chief Business Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | 10-Q | dcoy-20260331.htm |
| 2026-04-30 | 10-K/A | dcoy-20251231.htm |
| 2026-04-02 | S-8 | dcoy-20260402.htm |
| 2026-04-02 | 8-K | dcoy-20260331.htm |
| 2026-03-31 | 10-K | dcoy-20251231.htm |
| 2026-03-05 | 8-K | dcoy-20260305.htm |
| 2026-02-25 | 8-K | dcoy-20260224.htm |
| 2026-01-09 | DEF 14A | d70714ddef14a.htm |
| 2026-01-08 | 8-K | flks-20260108.htm |